Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Cash from Financing Activities of -$30.2 million for Q1 2026, down 108.28% year-over-year from $364.8 million in Q1 2025, and down 64.41% quarter-over-quarter from -$18.4 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at -$30.2 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 108.28% year-over-year to -$30.2 million; the TTM figure through Mar 2026 stood at -$83.1 million (down 1.53% YoY), while the FY2025 annual figure was -$67.4 million, up 16.71% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$30.2 million, down from -$18.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $428.1 million in Q2 2023, with the low at -$47.1 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is -$13.9 million (2022), against an average of $14.7 million.
- Peak annual rise in Cash from Financing Activities reached 43169.52% in 2023, while the deepest fall reached 391.48% in 2023.
- Amphastar Pharmaceuticals' Cash from Financing Activities stood at -$16.2 million in 2022, then plunged by 191.32% to -$47.1 million in 2023, then increased by 28.12% to -$33.8 million in 2024, then soared by 45.71% to -$18.4 million in 2025, then plunged by 64.41% to -$30.2 million in 2026.
- Business Quant data shows AMPH's Cash from Financing Activities at -$30.2 million in Q1 2026, -$18.4 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 942.71 Mn | 652.59 Mn | 93.47 Mn | -43.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.54 Mn |
| Jun 30, 2026 | -43.54 Mn |
| Mar 31, 2026 | -30.21 Mn |
| Mar 31, 2026 | -30.21 Mn |
| Dec 31, 2025 | -18.37 Mn |
| Dec 31, 2025 | -18.37 Mn |
| Sep 30, 2025 | -4.35 Mn |
| Sep 30, 2025 | -4.35 Mn |
| Jun 30, 2025 | -30.20 Mn |
| Jun 30, 2025 | -30.20 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -33.84 Mn |
| Dec 31, 2024 | -33.84 Mn |
| Sep 30, 2024 | -22.82 Mn |
| Sep 30, 2024 | -22.82 Mn |
| Jun 30, 2024 | -10.72 Mn |
| Jun 30, 2024 | -10.72 Mn |
| Mar 31, 2024 | -13.58 Mn |
| Mar 31, 2024 | -13.58 Mn |